636 results on '"Miners, John O."'
Search Results
2. Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance
3. Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs
4. Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs)
5. Binding of clozapine to the GABAB receptor: clinical and structural insights
6. Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma
7. Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure
8. Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity
9. A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: A platform for optimised KI dosing
10. Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer
11. The In Vitro Characterization of Inhibitory Drug–Drug Interactions Involving UDP-Glucuronosyltransferase
12. Response to in vitro and physiologically‐based pharmacokinetic assessment of the drug–drug interaction potential of canagliflozin
13. Novel advances in biotransformation and bioactivation research – 2020 year in review
14. Advances in drug metabolism and pharmacogenetics research in Australia
15. Inhibitory effects of non-steroidal anti-inflammatory drugs on human liver microsomal morphine glucuronidation: Implications for drug-drug interaction liability
16. Molecular dynamics simulations: from structure function relationships to drug discovery
17. Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins
18. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions
19. Scaling factors for the in vitro–in vivo extrapolation (IV–IVE) of renal drug and xenobiotic glucuronidation clearance
20. Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy
21. Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs
22. Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs)
23. Identification of UDP Glycosyltransferase 3A1 as a UDP N-Acetylglucosaminyltransferase
24. In vitro–in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance
25. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A
26. Assessment of inter-individual variability in predicted phenytoin clearance
27. Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping
28. Effect of concomitant use of antihypertensives and immune check point inhibitors on cancer outcomes
29. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)
30. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate
31. Arginine-259 of UGT2B7 Confers UDP-Sugar Selectivity
32. Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity
33. The In Vitro Characterization of Inhibitory Drug–Drug Interactions Involving UDP-Glucuronosyltransferase
34. The glycosidation of xenobiotics and endogenous compounds: Versatility and redundancy in the UDP glycosyltransferase superfamily
35. Homodimerization of UDP-glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative dimerization domain by protein homology modeling
36. Whatʼs in a name?
37. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment
38. Differential disposition of intra-renal generated and preformed glucuronides: studies with 4-methylumbelliferone and 4-methylumbelliferyl glucuronide in the filtering and nonfiltering isolated perfused rat kidney
39. Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab
40. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen
41. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer
42. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity
43. Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma
44. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202
45. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: Inhibition by NSAIDs
46. Macrolide–theophylline interactions: no role for the inhibition of cytochrome P4501A2
47. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway
48. Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants
49. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination
50. Quality of requests for serum digoxin concentrations: experience from an Australian Regional Health Service
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.